Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600 Variation Metastatic Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
JAMA Netw Open 2021 Nov 01;4(11)e2132262, C Cai, I Yunusa, A TarhiniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.